Bendamustine

Generic Name
Bendamustine
Brand Names
Belrapzo, Bendeka, Treanda, Vivimusta
Drug Type
Small Molecule
Chemical Formula
C16H21Cl2N3O2
CAS Number
16506-27-7
Unique Ingredient Identifier
9266D9P3PQ
Background

Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...

Indication

Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions
Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
Associated Therapies
-
Clinical Trials
Related News

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

First Posted Date
2011-06-09
Last Posted Date
2017-09-15
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
15
Registration Number
NCT01369849
Locations
🇺🇸

Metro-Minnesota NCI Community Oncology Research Program, Saint Louis Park, Minnesota, United States

🇺🇸

Minnesota Oncology and Hematology PA-Woodbury, Woodbury, Minnesota, United States

🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

and more 41 locations

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

First Posted Date
2011-05-11
Last Posted Date
2018-05-25
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
10
Registration Number
NCT01352312
Locations
🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

First Posted Date
2011-04-11
Last Posted Date
2022-08-11
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1401
Registration Number
NCT01332968
Locations
🇨🇦

North York General Hospital, Toronto, Ontario, Canada

🇦🇺

St Vincent'S Hospital; Haematology, Fitzroy, Victoria, Australia

🇨🇦

Humber River Hospital, Toronto, Ontario, Canada

and more 180 locations

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

First Posted Date
2011-03-31
Last Posted Date
2019-12-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
43
Registration Number
NCT01326702
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

First Posted Date
2011-03-17
Last Posted Date
2017-06-28
Lead Sponsor
Aptevo Therapeutics
Target Recruit Count
12
Registration Number
NCT01317901
Locations
🇺🇸

Site Reference ID/Investigator# 61523, Omaha, Nebraska, United States

🇺🇸

Site Reference ID/Investigator# 61542, Augusta, Georgia, United States

🇺🇸

Site Reference ID/Investigator# 61522, Hackensack, New Jersey, United States

and more 3 locations

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Phase 2
Terminated
Conditions
Multiple Myeloma
Interventions
Drug: Bendamustine
Drug: Bortezomib
First Posted Date
2011-03-15
Last Posted Date
2018-02-07
Lead Sponsor
NYU Langone Health
Target Recruit Count
24
Registration Number
NCT01315873
Locations
🇺🇸

New York University Langone Medical Center, New York, New York, United States

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

First Posted Date
2011-02-21
Last Posted Date
2017-02-02
Lead Sponsor
Genentech, Inc.
Target Recruit Count
41
Registration Number
NCT01300247

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

First Posted Date
2011-02-11
Last Posted Date
2018-08-09
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
49
Registration Number
NCT01294579
Locations
🇺🇸

Novartis Investigative Site, Yakima, Washington, United States

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

First Posted Date
2011-01-31
Last Posted Date
2024-11-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
135
Registration Number
NCT01286272
Locations
🇺🇸

Springfield Memorial Hospital, Springfield, Illinois, United States

🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

Saint Helena Hospital, Saint Helena, California, United States

and more 93 locations

GIMEMA CLL0809 Study (BendOfa)

First Posted Date
2010-11-19
Last Posted Date
2019-01-25
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
49
Registration Number
NCT01244451
Locations
🇮🇹

Azienda Sanitaria di Bolzano - Ospedale Centrale - Ematologia e Centro TMO, Bolzano, Italy

🇮🇹

Messina Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti "Papardo Piemonte", Messina, Italy

🇮🇹

Policlinico di Careggi, Università delgi studi di Firenze, Firenze, Italy

and more 29 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy